中金发表报告指,和誉-B(02256.HK) 于前日(22日)公告CSF-1R抑制剂匹米替尼(贝捷迈)在中国获批上市,用于不适合手术的腱鞘巨细胞瘤的治疗,这是公司第一个获批上市的自研创新药物。该行指,匹米替尼获批速度超该行预期,临床证据确凿。2025年6月,公司公告匹米替尼在中国的上市申请获得受理,到如今获批仅用了6个多月。此次获批基于匹米替尼全球III期注册临床MANEUVER研究的第一部分结果...
Source Link中金发表报告指,和誉-B(02256.HK) 于前日(22日)公告CSF-1R抑制剂匹米替尼(贝捷迈)在中国获批上市,用于不适合手术的腱鞘巨细胞瘤的治疗,这是公司第一个获批上市的自研创新药物。该行指,匹米替尼获批速度超该行预期,临床证据确凿。2025年6月,公司公告匹米替尼在中国的上市申请获得受理,到如今获批仅用了6个多月。此次获批基于匹米替尼全球III期注册临床MANEUVER研究的第一部分结果...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.